Epigenetic Changes in Psychotherapy of Adolescents With Borderline Personality Pathology

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04095546

Enrollment

Registered

2019-09-19

Start date

2022-04-30

Completion date

2024-12-31

Last updated

2022-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Personality Disorder (BPD)

Keywords

epigenetic changes, Psychotherapy, epigenetic regulation, methylation patterns, change in methylation of genes, FKBP5 gene

Brief summary

The link between epigenetic changes as an effect of psychotherapy has been investigated recently. Genes investigated in these studies were brain-derived neurotrophic factor (BDNF), NR3C1, FKBP51, MAOA and GLUT1. Change in methylation of these genes could be a biomolecular mechanism of psychotherapy induced changes. This study project aims at providing evidence for a biological mechanism of personality disorder interventions in adolescence by investigating the link between epigenetic changes as an effect of psychotherapy. It investigates the correlation between changes in the methylation of the FKBP5 gene and psychotherapy induced changes in symptoms and functioning.

Interventions

OTHERroutine psychotherapy for Borderline Personality Disorder (BPD)

Routine psychotherapy as treatment for patients with Borderline Personality Disorder

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

14 Years to 18 Years

Healthy volunteers

Inclusion criteria

* adolescents presenting 3 or more criteria for BPD in the Structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) axis II personality disorders (SCID-II)

Exclusion criteria

* difficulties to understand or comply with instructions * psychotic disorders * pervasive developmental disorders * severe somatic or neurological disorders * severe and persistent substance addiction * elevated risk for complications related to blood sampling

Design outcomes

Primary

Measure	Time frame	Description
change in methylation of the FKBP5 gene	after 6 months from baseline	change in methylation of the FKBP5 gene

Secondary

Measure	Time frame	Description
change in methylation of the FKBP5 gene	at month 3 and at month 12 after baseline.	change in methylation of the FKBP5 gene

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026